{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:36:51Z","timestamp":1793968611029,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["505558"],"award-info":[{"award-number":["505558"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.toxlet.2026.113188","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:01:31Z","timestamp":1788879691000},"page":"113188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Edaravone as an antioxidant adjuvant to attenuate clozapine toxicity in vitro"],"prefix":"10.1016","volume":"425","author":[{"given":"Dinesh","family":"Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7800-3650","authenticated-orcid":false,"given":"Thom H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepan","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1446-6369","authenticated-orcid":false,"given":"Newton H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4676-8161","authenticated-orcid":false,"given":"Phuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-9141","authenticated-orcid":false,"given":"Othman","family":"Eldalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4357-5586","authenticated-orcid":false,"given":"Lusine","family":"Tonoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-947X","authenticated-orcid":false,"given":"Arno G.","family":"Siraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.toxlet.2026.113188_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/pharmacy12030092","article-title":"Decoding clozapine-induced agranulocytosis: unraveling interactions and mitigation strategies","volume":"12","author":"Alalawi","year":"2024","journal-title":"Pharmacy"},{"issue":"11","key":"10.1016\/j.toxlet.2026.113188_bib2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/0018578717734877","article-title":"Formulary drug review: edaravone","volume":"52","author":"Ali","year":"2017","journal-title":"Hosp. Pharm."},{"issue":"4","key":"10.1016\/j.toxlet.2026.113188_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1139\/bcb-2014-0157","article-title":"Hyperbaric oxygen enhances neutrophil apoptosis and their clearance by monocyte-derived macrophages","volume":"93","author":"Almzaiel","year":"2015","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.toxlet.2026.113188_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JIR.S284941","article-title":"Studying neutrophil function in vitro: cell models and environmental factors","volume":"14","author":"Blanter","year":"2021","journal-title":"J. Inflamm. Res."},{"issue":"2","key":"10.1016\/j.toxlet.2026.113188_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/antiox11020195","article-title":"Effects of the edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection","volume":"11","author":"Cha","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.toxlet.2026.113188_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1023\/A:1016434312388","article-title":"Multiple-dose pharmacokinetics of clozapine in patients","volume":"4","author":"Choc","year":"1987","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.toxlet.2026.113188_bib7","first-page":"304","article-title":"More than 25 years of genetic studies of clozapine-induced agranulocytosis","volume":"17","author":"de With","year":"2017","journal-title":"Pharm. J."},{"issue":"8","key":"10.1016\/j.toxlet.2026.113188_bib8","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1021\/acs.molpharmaceut.8b00547","article-title":"Cellular uptake of the atypical antipsychotic clozapine is a carrier-mediated process","volume":"15","author":"Dickens","year":"2018","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.toxlet.2026.113188_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1179\/1351000215Y.0000000025","article-title":"Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone","volume":"21","author":"Fujisawa","year":"2016","journal-title":"Redox Report."},{"issue":"6","key":"10.1016\/j.toxlet.2026.113188_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0026-895X(24)13269-5","article-title":"A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol. Pharmacol."},{"issue":"Suppl","key":"10.1016\/j.toxlet.2026.113188_bib11","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1007\/BF00585923","article-title":"Myeloperoxidase of polymorphonuclear leukocytes in psoriasis vulgaris","volume":"279","author":"Greiten","year":"1987","journal-title":"Arch. Dermatol. Res."},{"issue":"1","key":"10.1016\/j.toxlet.2026.113188_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(98)00110-3","article-title":"Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis","volume":"131","author":"Guest","year":"1998","journal-title":"Toxicology"},{"issue":"1\u20133","key":"10.1016\/j.toxlet.2026.113188_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0300-483X(93)90066-2","article-title":"Myeloperoxidase-mediated activation of xenobiotics by human leukocytes","volume":"82","author":"Hofstra","year":"1993","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.toxlet.2026.113188_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/abbi.1999.1328","article-title":"Oxidation of clozapine and ascorbate by myeloperoxidase","volume":"368","author":"Hsuanyu","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"issue":"Pt 2","key":"10.1016\/j.toxlet.2026.113188_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1042\/bj3210503","article-title":"Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide","volume":"321","author":"Kettle","year":"1997","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.toxlet.2026.113188_bib16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/tx500019u","article-title":"Involvement of myeloperoxidase and NADPH oxidase in the covalent binding of amodiaquine and clozapine to neutrophils: implications for drug-induced agranulocytosis","volume":"27","author":"Lobach","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.toxlet.2026.113188_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxlet.2025.111752","article-title":"A chemoproteomic strategy for identifying protein covalent binding targets of clozapine: an approach for advancing clozapine toxicity research","volume":"414","author":"Lockhart","year":"2025","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.toxlet.2026.113188_bib18","first-page":"e33746","article-title":"Investigating edaravone use for management of amyotrophic lateral sclerosis (ALS): a narrative review","volume":"15","author":"Neupane","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.toxlet.2026.113188_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","article-title":"Worldwide differences in regulations of clozapine use","volume":"30","author":"Nielsen","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.toxlet.2026.113188_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hup.1181","article-title":"Haematological toxicity of clozapine and some other drugs used in psychiatry","volume":"26","author":"Nooijen","year":"2011","journal-title":"Human. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.toxlet.2026.113188_bib21","article-title":"Propofol inhibits the myeloperoxidase activity by acting as substrate through a redox process","volume":"1866","author":"Nyssen","year":"2022","journal-title":"Biochim. Et. Biophys. Acta General. Subj."},{"issue":"10","key":"10.1016\/j.toxlet.2026.113188_bib22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ijnp\/pyac036","article-title":"Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: a real-world nationwide study","volume":"25","author":"Ochi","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.toxlet.2026.113188_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116906","article-title":"Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients","volume":"415","author":"Ohta","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.toxlet.2026.113188_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cell.2017.10.011","article-title":"Edaravone: a new drug approved for ALS","volume":"171","author":"Rothstein","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.toxlet.2026.113188_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case\u2013control study in Finland","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.toxlet.2026.113188_bib26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/ijms24021243","article-title":"The role of myeloperoxidase in clozapine-induced inflammation: a mechanistic update for idiosyncratic drug-induced agranulocytosis","volume":"24","author":"Sernoskie","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxlet.2026.113188_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102109","article-title":"The many roles of myeloperoxidase: from inflammation and immunity to biomarkers, drug metabolism and drug discovery","volume":"46","author":"Siraki","year":"2021","journal-title":"Redox Biol."},{"issue":"7","key":"10.1016\/j.toxlet.2026.113188_bib28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/tx6003562","article-title":"Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis","volume":"20","author":"Siraki","year":"2007","journal-title":"Chem. Res. Toxicol."},{"issue":"2","key":"10.1016\/j.toxlet.2026.113188_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40263-023-01054-z","article-title":"Evaluating monitoring guidelines of clozapine-induced adverse effects: a systematic review","volume":"38","author":"Smessaert","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.toxlet.2026.113188_bib30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.freeradbiomed.2019.08.021","article-title":"Myeloperoxidase-mediated oxidation of edaravone produces an apparent non-toxic free radical metabolite and modulates hydrogen peroxide-mediated cytotoxicity in HL-60\u202fcells","volume":"143","author":"Suh","year":"2019","journal-title":"Free. Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.toxlet.2026.113188_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1189\/jlb.1112571","article-title":"What\u2019s your age again? Determination of human neutrophil half-lives revisited","volume":"94","author":"Tak","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.toxlet.2026.113188_bib32","article-title":"The oxidation of fenamic acid NSAIDs by neutrophil myeloperoxidase produces toxic reactive metabolites that induce leukemic cell death","volume":"5\u20136","author":"Tran","year":"2023","journal-title":"Redox Biochem. Chem."},{"issue":"1","key":"10.1016\/j.toxlet.2026.113188_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","article-title":"Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring","volume":"25","author":"Wici\u0144ski","year":"2018","journal-title":"Curr. Opin. Hematol."},{"issue":"10","key":"10.1016\/j.toxlet.2026.113188_bib34","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/tx034035z","article-title":"Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro","volume":"16","author":"Williams","year":"2003","journal-title":"Chem. Res. Toxicol."},{"issue":"5","key":"10.1016\/j.toxlet.2026.113188_bib35","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41401-025-01707-3","article-title":"Clozapine impaired the hypoglycemic effect of metformin by inhibiting hepatic organic cation transporter 1 (OCT1)","volume":"47","author":"Wu","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.toxlet.2026.113188_bib36","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/ijms25052945","article-title":"Update on antioxidant therapy with edaravone: expanding applications in neurodegenerative diseases","volume":"25","author":"Yamashita","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.toxlet.2026.113188_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/17482960600881870","article-title":"Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis","volume":"7","author":"Yoshino","year":"2006","journal-title":"Amyotroph. Lateral Scler."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427426013718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427426013718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:49:36Z","timestamp":1792680576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427426013718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S0378427426013718"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2026.113188","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Edaravone as an antioxidant adjuvant to attenuate clozapine toxicity in vitro","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2026.113188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113188"}}